Events

View All

    Advancing T cell Therapies Using B-hCD3 Mouse Models

    November 04, 2021
    Share on:

    Speaker: John Charpentier, PhD, Business Development Manager, Biocytogen Boston

     

    • Translational challenges in immunotherapy impede the successful transition of many therapeutic candidates to the clinic
    • Biocytogen’s humanized mice are rigorously designed and validated in the following ways to improve translation of CD3-targeting candidates: Expression (mRNA & flow cytometry), Immune cell frequency & maturation profiling and functional validation using reference antibodies whenever available
    • Humanized mice allow for robust preclinical modeling/testing for novel CD3-targeting therapies, including: Mono-and bispecific antibody candidates, Novel combination therapies, Preliminary toxicity assessments